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Circulating asymmetric (ADMA) and symmetric dimethylarginine (SDMA) are 
increased in patients with kidney disease. SDMA is considered a good marker of 
glomerular filtration rate (GFR) whilst ADMA is a marker of cardiovascular risk. 
However, a link between SDMA and all-cause mortality has been reported. In the 
present study we evaluated both dimethylarginines as risk and GFR markers in a 
cohort of elderly white individuals, both with and without CKD.
Methods
GFR was measured in 394 individuals aged >74 years using an iohexol clearance 
method. Plasma ADMA, SDMA and iohexol were measured simultaneously using 
isotope dilution tandem mass spectrometry.
Results
Plasma ADMA concentrations were increased (P<0.01) in people with GFR <60 
mL/min/1.73 m² compared to those with GFR >60 mL/min/1.73 m², but did not differ 
(P>0.05) between those with GFR 30-59 mL/min/1.73 m² and <30 mL/min/1.73 m². 
Plasma SDMA increased consistently across declining GFR categories (P<0.0001). 
GFR had an independent effect on plasma ADMA concentration whilst GFR, gender, 
body mass index and haemoglobin had independent effects on plasma SDMA 
concentration. Participants were followed for a median of 33 months. There were 65 
deaths. High plasma ADMA (P=0.0412) and SDMA (P<0.0001) concentrations were 
independently associated with reduced survival.
Conclusions
Amongst elderly white individuals with a range of kidney function, SDMA was a better 
marker of GFR and a stronger predictor of outcome than ADMA. Future studies 
should further evaluate the role of SDMA as a marker of outcome and assess its 
potential value as a marker of GFR.
Key words: ADMA, dimethylarginines, kidney disease, older people, SDMA 
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Dimethylarginines are produced in all nucleated cells as a result of methylation of 
arginine residues in proteins and subsequent release of free methylarginines 
following proteolysis.1 It is known that both asymmetric dimethylarginine (ADMA) and 
symmetric dimethylarginine (SDMA) are increased in the blood of patients with 
kidney failure.2, 3 ADMA has structural similarity to the amino acid L-arginine and acts 
as an endogenous inhibitor of nitric oxide synthesis: SDMA does not have this 
property.2 Consequently increased concentrations of ADMA have been associated 
with oxidative stress, inflammation, fibrogenesis and endothelial dysfunction and may 
contribute to both cardiovascular risk4, 5 and chronic kidney disease (CKD) 
progression.6-10 Given the strong association between cardiovascular disease and 
CKD11-13 there is interest in the use of ADMA as both a risk marker and promoter of 
cardiovascular disease progression in this setting. It is generally held that SDMA, 
which is mainly eliminated from the body by renal excretion,14 is a good marker of 
glomerular filtration rate (GFR) whilst ADMA is a good marker of cardiovascular risk. 
However, studies have also shown a strong and independent link between SDMA, 
all-cause mortality, and cardiovascular events.15 In the present study we have 
evaluated both dimethylarginines as risk and GFR markers in a large cohort of 
elderly white individuals, both with and without CKD, and in whom GFR has been 
characterised using a reference technique.
Materials and Methods
The study included a cohort of 394 white people aged 74 years and above as 
previously described.16 All subjects gave informed consent. The study took place in 
East Kent, a semirural area of Southern England.
GFR was measured using an iohexol clearance method as previously described.16 
Briefly, following intravenous injection of a 5 mL bolus of Omnipaque 240 (518 g/L 
iohexol corresponding to 240 g/L of iodine, GE Healthcare www.gelifesciences.com) 
lithium heparin blood samples were taken before and at 5, 120, 180 and 240 minutes 
after injection. 
Iohexol GFR was calculated using a single compartment model: 
GFR (mL/min) = 0.693 x iohexol volume of distribution (L) x 1000/half-life of iohexol 
(min)
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The GFR (mL/min) was corrected for body surface area and the Brochner-Mortensen 
correction applied.17
Plasma ADMA, SDMA, creatinine and iohexol were measured simultaneously in 
lithium heparin plasma using a modified stable isotope dilution electrospray tandem 
mass spectrometric method reported for creatinine18 with minor modification.16 ADMA 
and SDMA concentrations reported here were measured in blood obtained 
immediately prior to iohexol injection. Samples were thawed and mixed well, 50 µL of 
plasma was mixed with 50 G of deionized water containing 50 pmol of [2H6] ADMA 
and 50 pmol of [2H6] SDMA and precipitated with 200 G of acetonitrile. The stable 
isotopes for [2H6] ADMA and [2H6] SDMA, were synthesized by Department of 
Chemistry, King's College London, London, U.K. Following mixing and centrifugation 
for 3 min at 21800 g, the supernatants were transferred to a 96-deep-well plate. 
Supernatant (5 µL) was pipetted using an HTSPAL autosampler into a 250 G@' 
mobile-phase stream of acetonitrile/water (50:50; v/v) with 0.025% (v/v) formic acid. 
Chromatography was done on a Chirobiotic T 100 mm × 2.1 mm column with a 2 cm 
× 4 mm guard column (Advanced Separation Technologies) and precursor/product 
ion pairs (m/z 203.1/46.2 and 209.1/52.2 for ADMA and m/z 203.1/172.2 and 
209.1/175.1 for SDMA) were obtained in positive-ion multiple reaction monitoring 
method using a Sciex API4000 (Applied Biosystems). Assay standardization was 
based on aqueous standards at 0.25, 1.0 and 5.0 G'@ ADMA/SDMA stored at 
O1.P) For the internal quality control, pooled and spiked plasma samples were 
used. Intra-assay coefficients of variation were 2.1% at a concentration of 370 nmol/L 
for plasma ADMA and 3.5% at a concentration of 440 nmol/ L for plasma SDMA. 
Results were calculated using Analyst version 1.4.1.19 
Statistical analysis was performed using Analyse-it (Analyse-it Software, Ltd, 
Leeds, U.K.), InStat® (GraphPad® Software Inc, San Diego, USA) and StatsDirect 
(StatsDirect Ltd, Cheshire, UK). A P value of <0.05 was considered statistically 
significant. Most data, except haemoglobin, were not normally distributed (P<0.001, 
Shapiro-Wilk test) and all concentrations were expressed as median and interquartile 
range. Data were studied across GFR groups defined as >60, 30-59 and <30 
mL/min/1.73 m2. The Mann-Whitney U-test was used to compare data between two 
groups and the Kruskal-Wallis test (non-parametric analysis of variance (ANOVA)) to 
detect trends across more than two groups. Dunn's multiple comparison test was 
used to undertake pairwise comparisons if a significant effect was observed. 
Categorical variables were analysed using chi-squared test for trend. 
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Spearman rank analysis was used to test for univariate relationships between plasma 
ADMA and SDMA concentrations and other clinical variables including age, body 
mass index (BMI), mean arterial blood pressure (MABP), haemoglobin, GFR and 
plasma creatinine. Multiple linear regression analysis was used to assess the 
independent effect of clinical variables (age, gender, BMI, MABP, GFR, number of 
medications, haemoglobin, presence of vascular disease, hypertension and smoking 
status) on plasma ADMA and SDMA concentrations. Manual backward elimination 
was performed; clinical variables that were not significant (P>0.05) were eliminated 
from the analysis. Multicollinearity was not detected in any models used. 
Survival analysis (all-cause mortality) was studied using the Kaplan-Meier method. 
Significance between risk stratification groups (plasma ADMA and SDMA 
concentration above and below the median value) was determined using the 
Wilcoxon log-rank statistical test. Cox proportional hazard ratio was used to 
determine the association of variables with the risk of all cause death. Unadjusted 
hazard ratios (HRs) and the 95% confidence interval were calculated for plasma 
ADMA and SDMA concentration, age, gender, BMI, MABP, GFR, number of 
medications, haemoglobin concentration, diabetes mellitus, smoking status and 
hypertension. HRs and 95% confidence intervals were expressed per 1SD higher 
value of each variable for continuous variables. Cox regression analysis was 
performed with adjustment for the significant variables. Manual backward elimination 
was performed; clinical variables that were not significant (P>0.05) were excluded 
from the analysis. Multicollinearity was not detected in any models used.
Results
The East Kent cohort has been described previously.16 Briefly, subjects ranged in 
age from 74 to 97 years and were exclusively white. Approximately equal numbers of 
men and women were included. Characteristics overall and by GFR category are 
summarised in Table 1. Age and number of medications increased and haemoglobin 
concentration decreased with declining GFR. The prevalence of vascular disease, 
diabetes mellitus and hypertension increased with declining GFR. 
Plasma ADMA concentrations were increased (P<0.01) in people with GFR <60 
mL/min/1.73 m² compared to those with GFR >60 mL/min/1.73 m², but did not differ 
(P>0.05) between GFR category 30-59 mL/min/1.73 m² and <30 mL/min/1.73 m². 
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Conversely plasma SDMA increased consistently across declining GFR categories 
(P<0.0001)(Table 1). In univariate analyses both plasma ADMA and SDMA 
concentrations increased with declining GFR (Table 2, Figure 1). Plasma SDMA but 
not ADMA concentration was positively correlated (P<0.0001) with age (Table 2). 
Plasma SDMA concentration (median, interquartile range) was significantly higher 
(P<0.0001) in males (762, 627 to 1033 nmol/L) than in females (617, 513 to 823 
nmol/L): plasma ADMA concentration did not differ between genders (P>0.05). 
GFR was the only variable which had an independent effect on plasma ADMA 
concentration. The fit (R²) of the model including GFR as a variable was 0.20. GFR, 
gender, BMI and haemoglobin had independent effects on plasma SDMA 
concentration. The overall fit (R²) of the model including these three variables was 
0.69 (P<0.0001)(Table 3).
All participants were followed up for a median (interquartile range) period of 33 (26-
43) months. During the follow up period, 65 people died. Seventy-two percent of the 
individuals that died had plasma ADMA concentrations greater than or equal to the 
median plasma ADMA concentration 4U7;- nmol/L). When the end point of the follow 
up period was considered as 48 months the survival chances for people with plasma 
ADMA concentrations U7;- nmol/L compared to <543 nmol/L were 68% and 89% 
respectively (P=0.0009) (Figure 2). The median plasma SDMA concentration was 
680 nmol/L: 83% of the individuals that died had plasma SDMA concentrations U01. 
nmol/L. When the end point of the follow up period was considered as 48 months the 
survival chances for people with plasma SDMA concentrations U01. nmol/L 
compared to <680 nmol/L were 65% and 93% respectively (P<0.0001)(Figure 2).
Cox proportional hazard ratios were calculated to determine the significance of 
variables as predictors of all cause death. In unadjusted analyses ADMA, SDMA, 
age, GFR, number of medications, haemoglobin, presence of vascular disease and 
smoking status were significant predictors (Table 4). Manual backward elimination 
with stepwise elimination of insignificant variables was undertaken in two separate 
models including ADMA or SDMA. In the final ADMA model age, GFR, presence of 
vascular disease and smoking status in addition to plasma ADMA concentration 
remained significant independent predictors of all cause death. In the final SDMA 
model age and smoking status in addition to plasma SDMA concentration remained 
significant (Table 4).  
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To our knowledge this is the first study to evaluate ADMA and SDMA as markers of 
both GFR and outcome in an exclusively elderly cohort across a range of kidney 
function in conjunction with a reference GFR measurement. In this study both ADMA 
and SDMA were inversely related to GFR. This relationship was stronger for SDMA 
than ADMA. Whilst ADMA concentration was influenced by GFR only, SDMA 
concentration was also affected by gender, BMI and haemoglobin concentration. 
ADMA predicted mortality risk, but this effect only just achieved significance with age, 
GFR, presence of vascular disease and smoking history all contributing strongly and 
independently to risk. Conversely, SDMA was a highly significant predictor of death 
in this cohort, with age and smoking history but not GFR contributing to risk in this 
model.
The strength of the relationship we observed between GFR and ADMA (rs -0.42) is 
broadly similar to that observed in other cohorts (r -0.24,9 r -0.29,5 r -0.2620), and not 
of sufficient strength to suggest that ADMA could be a useful marker on its own of 
GFR. Whilst SDMA is mainly eliminated through the kidneys,14 ADMA is mainly 
metabolised through enzymatic degradation in both the liver and kidney involving 
dimethylarginine dimethylaminohydrolase (DDAH). Consequently the relationship 
between ADMA and GFR may be confounded by hepatic function.21-23 In a 
retrospective analysis of participants in the Modification of Diet in Renal Disease 
Study, Young et al also found GFR to be the only variable tested to be significantly 
associated with ADMA concentration, but their model only explained 5% of the 
variability in ADMA concentration.24
There has been extensive study of the relationship between SDMA and GFR.25 
SDMA shows some of the properties of an ideal glomerular filtration marker, 
including being produced at a constant rate and being almost completely eliminated 
from the body by renal excretion.14 The strong relationship we have observed 
between SDMA and GFR (rs -0.87) is consistent with that from other studies,20, 25, 26 
particularly those that also used a reference GFR technique where observed 
correlation coefficients ranged from 0.78 to 0.90.25 The SDMA-GFR relationship was 
also similar to that we observed between serum creatinine and GFR (rs -0.87) and 
for the proposed GFR marker cystatin C (rs -0.90, data not shown) in this group. 
SDMA has also been shown to be an early and sensitive marker of abrupt change in 
kidney function following kidney donation.27 In addition to being related to GFR, 
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plasma SDMA concentration is also strongly affected by gender, raising the 
possibility that GFR prediction from SDMA could be improved by models that also 
take gender into account.
Given the clear pathophysiological construct linking ADMA and vascular dysfunction, 
many studies have addressed the relationship between increased circulating ADMA 
concentration and mortality risk across a variety of populations,22, 28-30 including 
amongst older people.31 In the setting of kidney disease, an early study in dialysis 
patients showed that ADMA, but not SDMA, predicted mortality.32 In several cohorts 
of CKD patients, and amongst renal transplant recipients,33 high ADMA concentration 
was an independent predictor of all-cause mortality.5, 9 Conversely, in the study of 
Young et al amongst patients with moderate to severe CKD, ADMA did not reach 
significance as an independent predictor of all-cause mortality, although it was a 
significant predictor of cardiovascular mortality.24 
Fewer studies have explored the relationship between SDMA and mortality risk but 
increasing evidence suggests a role. In a German study of individuals receiving 
coronary angiography following an ischaemic event, SDMA demonstrated a J-shaped 
relationship with all-cause and cardiovascular mortality whereas the ADMA-mortality 
relationship was more linear.26 SDMA, but not ADMA, was independently associated 
with survival after stroke,34 non-ST elevation myocardial infarction20 and amongst 
individuals admitted to an intensive care unit.35 
Part of the association between SDMA and risk of mortality may reflect the strong 
relationship between GFR itself and risk. Indeed, the strong relationship between 
SDMA and GFR probably explains why only one of these factors remained significant 
in our adjusted model. A relationship between SDMA and mortality independent of 
GFR has also been reported in renal transplant recipients.36 Recent evidence 
suggests potential direct pathophysiological links between SDMA and cardiovascular 
disease through indirect inhibition of nitric oxide synthesis.15 The proposed 
mechanism is through competition with L-arginine for transport, hence limiting the 
availability of L-arginine to nitric oxide synthase.37 In turn, reactive oxygen species 
may further promote intracellular ADMA formation.38  Dose-dependent inhibition of 
nitric oxide synthesis by SDMA has been observed in cultured endothelial cells, 
coupled with increased production of reactive oxygen species.15 In vitro SDMA, but 
not ADMA, was shown to cause release of proinflammatory cytokines (interleukin-6, 
IL-6; tumour necrosis factor-a, TNF-a) from monocytes: release of cytokines was 
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linked to activation of nuclear factor-Kappa B.39 In vivo, plasma SDMA concentration 
was correlated to IL-6 and TNF-a concentrations amongst patients with CKD, with 
much weaker relationships observed for ADMA and cytokine concentrations.39 
SDMA, but not ADMA, concentrations have previously been observed to be 
independently increased in patients with coronary vascular disease and related to 
extent of such disease.15 There is therefore increasing evidence suggesting that 
SDMA could contribute to endothelial dysfunction and the chronic inflammatory state 
characteristic of CKD, with attendant increase in cardiovascular risk.
The strengths of this study include the simultaneous measurement of ADMA and 
SDMA across a well-characterised, large number of subjects covering a spectrum of 
kidney disease assessed using a reference GFR technique. The study has some 
limitations. Only single baseline measures of the dimethylarginines were available. 
Only all-cause mortality data was collected: pathophysiologically one would 
anticipate the role of dimethylarginines to be more closely linked to cardiovascular 
mortality. However, although cardiovascular disease is the major cause of mortality 
amongst people with CKD,12 other pathology including malignancy and infection40 
could be contributing to the relationship between mortality and SDMA due to 
increased SDMA production as a result of increased cell turnover. The study was 
exclusively white and findings may therefore not hold in other ethnic groups.41 In 
common with most studies in this field, plasma concentrations of dimethylarginines 
were measured. Any effects in vivo are likely to be related to intracellular 
dimethylarginine concentrations. Plasma concentrations of dimethylarginines may not 
reflect their intracellular concentration, potentially obscuring their true relationship 
with mortality.42
In conclusion we have shown that amongst elderly white individuals and across a 
range of kidney function, SDMA appears to be both a better marker of GFR and a 
stronger predictor of outcome than ADMA. The prognostic power of SDMA may be 
related to its more recently described roles in stimulating the pro-inflammatory state. 
Future studies should further evaluate the role of SDMA as a marker of outcome and 
assess its potential value as a marker of GFR.
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Figure 1A. Scatter plot of 1/plasma ADMA in association with measured 
glomerular filtration rate (mGFR). rs = 0.42, p <0.0001
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Figure 1B. Scatter plot of 1/plasma SDMA in association with measured 
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Figure 2a. Kaplan-Meier survival curve by median ADMA concentration (543 nmol/L); P=0.0009.
 ADMA 8 543 nmol/L
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Figure 2b. Kaplan-Meier survival curve by median SDMA concentration (680 nmol/L); P<0.0001.
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Table 1. Subject characteristics by GFR category. Values for continuous variables are expressed as median (interquartile range) unless 
stated otherwise. P<0.05 was considered significant. 
Total cohort 8;+ mL/min/1.73 m² 3059 mL/min/1.73 m² <30 mL/min/1.73 m² P for trend
n  394 163 171 60 -
Male:female, n (% male) 189:205 67:96 (41) 90:81 (53) 33:28 (55) 0.0617
Age, y 80 (77-83) 79 (76-81)a, b 80 (77-84) 81 (77-86) <0.0001
BMI, weight(kg)/height(m)² 26.1 (23.6-29.3) 25.8 (23.1-28.6) 26.2 (24.1-29.7) 27.3 (23.9-30.0) 0.0998
MABP, mm Hg* 96.0 (89.3-103.6) 94.3 (87.3-104.4) 96.6 (91.4-104.8) 96.3 (87.1-100.9) 0.4100
Number of medications, n 5 (3-8) 4 (1-6)a, b 6 (4-8) 7 (5-10) <0.0001
Vascular disease, n (%) 172 (44) 49 (31)a 90 (53) 33 (54) <0.0001
Diabetes, n (%) 77 (20) 21 (13)b 36 (21) 20 (33) 0.0032
Hypertension, n (%) 251 (55) 71 (44)a, b 104 (61) 40 (66) 0.0014
Smoker, n (%) 86 (22) 26 (16)a 51 (30)c 9 (15) 0.0034
Haemoglobin, g/L 130 (120-139) 136 (129-142)a, b 126 (117-136)c 118 (118-129) <0.0001
Serum creatinine, µmol/L 95 (73-144) 71 (61-84) 111 (88-145) 191 (157-247) -
GFR, mL/min/1.73 m² 53 (35-68) 69 (64-78) 45 (36-52) 25 (22-27) -
ADMA, nmol/L 543 (498- 608) 521 (472-559) a, b 565 (513-624) 595 (526-673) <0.0001
SDMA, nmol/L 680 (542-927) 530 (480-610) a, b 775 (663-934)c 1220 (1067-1390) <0.0001
*MABP data was obtained for 374 patients in total and 154, 163 and 57 patients in the >60, 30-59 and <30 mL/min/1.73 m2 groups respectively.
Abbreviations: ADMA, asymmetric dimethylarginine; BMI, Body mass index; GFR, measured glomerular filtration rate (using iohexol); MABP, mean arterial 
blood pressure; SDMA, symmetric dimethylarginine;.
Dunn's multiple comparison test for pairwise comparisons of the effect of GFR category on plasma ADMA, SDMA and serum cystatin C concentration are 
denoted as shown below.
a P<0.05 for U0. mL/min/1.73 m² vs. 30-59 mL/min/1.73 m²
b P<0.05 for U0. mL/min/1.73 m² vs. <30 mL/min/1.73 m²
c P<0.05 for 30-59 mL/min/1.73 m² vs. <30 mL/min/1.73 m²
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Serum creatinine 0.34 0.87
Note. Values expressed as correlation coefficients obtained using Spearmans rank statistic. Statistical significance is shown as  (P<0.0001 in each case); 
the remaining correlations were not statistically significant.
Abbreviations: ADMA, asymmetric dimethylarginine; BMI, body mass index; GFR, measured glomerular filtration rate (using iohexol); MABP, mean arterial 
blood pressure; SDMA, symmetric dimethylarginine; 
Page 20 of 47
















































Table 3. Effect of clinical variables on plasma ADMA and SDMA concentrations. Values shown are the beta coefficients (95% confidence 
intervals) for the variables that remained significant in the multiple regression model.
ADMA SDMA
Constant 664.1 (641.5 to 686.6), P<0.0001 1828.1 (1654.1 to 2002.0), P<0.0001
Glomerular filtration rate -2.032 (-2.436 to -1.628), P<0.0001 -11.779 (-12.791 to -10.768), P<0.0001
Haemoglobin - -2.723   (-3.968 to -1.478), P<0.0001
Gender - 98.416 (63.281 to 133.55), P<0.0001
Body mass index - -4.907 (-8.699 to -1.116), P=0.0116
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Table 4. Unadjusted and adjusted hazard ratios for death. For continuous variables, the hazard ratios are expressed as the increased risk 
associated with a one standard deviation increase (ADMA, age, BMI, MABP, medication no.) or decrease (GFR, haemoglobin). For categorical 
variables, the hazard ratios are expressed as risk if conditions present (vascular disease, hypertension, smoker and diabetes mellitus) or if 
female rather than male, compared to risk in the absence of condition.
Variable Unadjusted hazard 








ratio (95% CI) per 
standard deviation
P 
ADMA, nmol/ L 1.67 (1.32 - 2.10) <0.0001 1.30 (1.01-1.68) 0.0412 - -
SDMA, nmol/L 2.01 (1.66 - 2.44) <0.0001 - - 2.43 (1.80  3.28)  <0.0001
Age, years 1.65 (1.36  2.00) <0.0001 1.43 (1.17  1.75) 0.0005 1.47 (1.20 - 1.81) 0.0003
Gender (f/m) 1.42 (0.87 - 2.32) 0.1651a - -
BMI, weight(kg)/height(m)² 0.95 (0.74 - 1.21) 0.6593 - -
MABP, mmHg 0.99 (0.77 - 1.27) 0.9265 - -
GFR, mL/min/1.73 m² 0.44 (0.33 - 0.59) <0.0001 0.54 (0.39  0.76) 0.0003
Number of medications, n 1.39 (1.11 - 1.75) 0.0045 - -
Haemoglobin, g/L 0.63 (0.46 - 0.85) 0.0032 - -
Vascular Disease (y/n) 2.61 (1.56  - 4.37) 0.0162a 1.91 (1.14  3.21)a 0.0145
Diabetes (y/n) 1.42 (0.82 - 2.48) 0.2143a - -
Smoker (y/n) 2.14 (1.30 - 3.53) 0.0029a 1.87 (1.13  3.10)a 0.0155 1.99 (1.20 - 3.29)a 0.0074
Hypertension (y/n) 1.38 (0.84 - 2.29) 0.2061a - -
Abbreviations: ADMA, asymmetric dimethylarginine; BMI, Body mass index;  CI, confidence interval; GFR, glomerular filtration rate (using iohexol); MABP, 
mean arterial blood pressure; SDMA, symmetric dimethylarginine
a adjusted hazard ratio (95% CI) for presence compared to absence or female versus male
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Annals of Clinical Biochemistry
Dear Maurice,
Re: Manuscript ID ACB-18-185 entitled "Symmetric dimethylarginine (SDMA) is a stronger predictor of mortality risk than 
asymmetric dimethylarginine (ADMA) amongst older people with kidney disease"
Thank you for returning our manuscript. We were pleased with the generally encouraging responses 
from the referees.
Specifically in response to their points (our responses in bold):
Referee: 1
1.  The data in table 1 are stated in to be presented as median (interquartile range), but the range in 
brackets in fact appears to be the absolute range, which is consistent with what is stated in the 
methods (page 4, final paragraph).  Presentation as median (IQR) would be preferable.  Similarly the 
data presented textually for sex differences in SDMA (page 6, first paragraph) could be presented in 
this way.
ogise for this. been included.
2. In the discussion (page 7, 2nd paragraph), the final r value presented in brackets should 
presuma
Thank you for spotting this error. It has been amended to -0.26.
3.  I would like to clarify whether the SDMA model which reports an adjusted HR of 2.43 per SD is 
adjusted for GFR, i.e. whether it could be said that SDMA adds anything over GFR for risk prediction, 
or whether SDMA is merely a marker of GFR, given the strong correlation between GFR and SDMA. 
This possibility is indeed acknowledged by the authors in the discussion (page 8); the cited study by 
s an independent effect of SDMA on all-cause mortality only in quartile 4 vs 
quartile 1, and the SDMA concentrations in the present study are lower than th
GFR wa from the adjusted SDMA model and we feel we have made this clear in the 
manuscript. In the results secti the final SDMA model age and smoking 
status in addition to plasma SDMA concentration remained significant (Table 4). In the 
on this furthe f the association between SDMA and risk of 
mortality may reflect the strong relationship between GFR itself and risk. Indeed, the strong 
relationship between SDMA and GFR pro y only one of these factors 
remained significant in our ad hat is interesting is that SDMA pushes GFR out 
of the model, suggesting that it is indeed closely related to GFR but is also contributing 
something else in terms of risk assessment.
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 not fully understand the comment regarding Reported SDMA 
concentrations will be affected by the method used: we used IDMS, 
rtheless, the results are broadly comparable e.g. Pihlstroms Q4 (mean eGFR 35 mL/min) 
had SDMA concentrations ranging from 1380 to 4410 nmol/L, compared to the group with 
GFR<30 in the present study (median mGFR 25 mL/min) where SDMA concentrations ranged 
from 708 to 2240 nmol/L.
4.  Data are presented for all-cause mortality.  Is it possible to refine this by cause of death to see 
whether CV death is specifically associated with SDMA/ADMA in this population?  Given the 
hypothesised effects of dimethylarginines CV death in particular would be of interest.
We agree with the reviewer on this point but unfortunately we did not collect cause of death 
data. We acknowledge this as a limitation of the study in the Discussion, whilst also discussing 
that increased dimethylarginine concentrations may reflect other non-cardiac pathology that 
contributes to mortality in CKD.
Referee: 2
Comments to the Author
I was impressed with this paper. It uses clear methodology to establish a link between the molecules 
studied and clinical outcomes. The statistics used seem appropriate. It adds to the evidence base with 
regard to the increased risk of adverse outcomes associated with Chronic Kidney Disease. As well as 
a marker for outcomes this may lead to potential therapeutic targets. I would have liked to have seen if 
there was a correlation with a measure of proteinuria as a clinical variable, particularly as this is an 
established risk factor for cardiovascular disease. Similarly I would have liked to have seen whether 
there is a correlation between the primary renal diagnosis and ADMA and SDMA concentrations. It 
might be worthwhile for the authors to consider adding these variables to future research but  overall I 
don't think these omissions detract from the paper.
We are grateful to reviewer 2 for his encouraging comments. Unfortunately we are unable to 
undertake the analyses he has suggested in this cohort.




Dr Edmund Lamb PhD FRCPath
Clinical Director of Pathology and Consultant Clinical Scientist (Biochemistry)
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Circulating asymmetric (ADMA) and symmetric dimethylarginine (SDMA) are 
increased in patients with kidney disease. SDMA is considered a good marker of 
glomerular filtration rate (GFR) whilst ADMA is a marker of cardiovascular risk. 
However, a link between SDMA and all-cause mortality has been reported. In the 
present study we evaluated both dimethylarginines as risk and GFR markers in a 
cohort of elderly white individuals, both with and without CKD.
Methods
GFR was measured in 394 individuals aged >74 years using an iohexol clearance 
method. Plasma ADMA, SDMA and iohexol were measured simultaneously using 
isotope dilution tandem mass spectrometry.
Results
Plasma ADMA concentrations were increased (P<0.01) in people with GFR <60 
mL/min/1.73 m² compared to those with GFR >60 mL/min/1.73 m², but did not differ 
(P>0.05) between those with GFR 30-59 mL/min/1.73 m² and <30 mL/min/1.73 m². 
Plasma SDMA increased consistently across declining GFR categories (P<0.0001). 
GFR had an independent effect on plasma ADMA concentration whilst GFR, gender, 
body mass index and haemoglobin had independent effects on plasma SDMA 
concentration. Participants were followed for a median of 33 months. There were 65 
deaths. High plasma ADMA (P=0.0412) and SDMA (P<0.0001) concentrations were 
independently associated with reduced survival.
Conclusions
Amongst elderly white individuals with a range of kidney function, SDMA was a better 
marker of GFR and a stronger predictor of outcome than ADMA. Future studies 
should further evaluate the role of SDMA as a marker of outcome and assess its 
potential value as a marker of GFR.
es, kidney disease, older people, SDMA 
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Dimethylarginines are produced in all nucleated cells as a result of methylation of 
arginine residues in proteins and subsequent release of free methylarginines 
following proteolysis.1 It is known that both asymmetric dimethylarginine (ADMA) and 
symmetric dimethylarginine (SDMA) are increased in the blood of patients with 
kidney failure.2, 3 ADMA has structural similarity to the amino acid L-arginine and acts 
as an endogenous inhibitor of nitric oxide synthesis: SDMA does not have this 
property.2 Consequently increased concentrations of ADMA have been associated 
with oxidative stress, inflammation, fibrogenesis and endothelial dysfunction and may 
contribute to both cardiovascular risk4, 5 and chronic kidney disease (CKD) 
progression.6-10 Given the strong association between cardiovascular disease and 
CKD11-13 there is interest in the use of ADMA as both a risk marker and promoter of 
cardiovascular disease progression in this setting. It is generally held that SDMA, 
which is mainly eliminated from the body by renal excretion,14 is a good marker of 
glomerular filtration rate (GFR) whilst ADMA is a good marker of cardiovascular risk. 
However, studies have also shown a strong and independent link between SDMA, 
all-cause mortality, and cardiovascular events.15 In the present study we have 
evaluated both dimethylarginines as risk and GFR markers in a large cohort of 
elderly white individuals, both with and without CKD, and in whom GFR has been 
characterised using a reference technique.
Materials and Methods
The study included a cohort of 394 white people aged 74 years and above as 
previously described.16 All subjects gave informed consent. The study took place in 
East Kent, a semirural area of Southern England.
GFR was measured using an iohexol clearance method as previously described.16 
Briefly, following intravenous injection of a 5 mL bolus of Omnipaque 240 (518 g/L 
iohexol corresponding to 240 g/L of iodine, GE Healthcare www.gelifesciences.com) 
lithium heparin blood samples were taken before and at 5, 120, 180 and 240 minutes 
after injection. 
Iohexol GFR was calculated using a single compartment model: 
GFR (mL/min) = 0.693 x iohexol volume of distribution (L) x 1000/half-life of iohexol 
(min)
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The GFR (mL/min) was corrected for body surface area and the Brochner-Mortensen 
correction applied.17
Plasma ADMA, SDMA, creatinine and iohexol were measured simultaneously in 
lithium heparin plasma using a modified stable isotope dilution electrospray tandem 
mass spectrometric method reported for creatinine18 with minor modification.16 ADMA 
and SDMA concentrations reported here were measured in blood obtained 
immediately prior to iohexol injection. Samples were thawed and mixed well, 50 µL of 
plasma was mixed with 50 G of deionized water containing 50 pmol of [2H6] ADMA 
and 50 pmol of [2H6] SDMA and precipitated with 200 G of acetonitrile. The stable 
isotopes for [2H6] ADMA and [2H6] SDMA, were synthesized by Department of 
Chemistry, King's College London, London, U.K. Following mixing and centrifugation 
for 3 min at 21800 g, the supernatants were transferred to a 96-deep-well plate. 
Supernatant (5 µL) was pipetted using an HTSPAL autosampler into a 250 G@' 
mobile-phase stream of acetonitrile/water (50:50; v/v) with 0.025% (v/v) formic acid. 
Chromatography was done on a Chirobiotic T 100 mm × 2.1 mm column with a 2 cm 
× 4 mm guard column (Advanced Separation Technologies) and precursor/product 
ion pairs (m/z 203.1/46.2 and 209.1/52.2 for ADMA and m/z 203.1/172.2 and 
209.1/175.1 for SDMA) were obtained in positive-ion multiple reaction monitoring 
method using a Sciex API4000 (Applied Biosystems). Assay standardization was 
based on aqueous standards at 0.25, 1.0 and 5.0 G'@ ADMA/SDMA stored at 
O1.P) For the internal quality control, pooled and spiked plasma samples were 
used. Intra-assay coefficients of variation were 2.1% at a concentration of 370 nmol/L 
for plasma ADMA and 3.5% at a concentration of 440 nmol/ L for plasma SDMA. 
Results were calculated using Analyst version 1.4.1.19 
Statistical analysis was performed using Analyse-it (Analyse-it Software, Ltd, 
Leeds, U.K.), InStat® (GraphPad® Software Inc, San Diego, USA) and StatsDirect 
(StatsDirect Ltd, Cheshire, UK). A P value of <0.05 was considered statistically 
significant. Most data, except haemoglobin, were not normally distributed (P<0.001, 
Shapiro-Wilk test) and all concentrations were expressed as median and interquartile 
range. Data were studied across GFR groups defined as >60, 30-59 and <30 
mL/min/1.73 m2. The Mann-Whitney U-test was used to compare data between two 
groups and the Kruskal-Wallis test (non-parametric analysis of variance (ANOVA)) to 
detect trends across more than two groups. Dunn's multiple comparison test was 
used to undertake pairwise comparisons if a significant effect was observed. 
Categorical variables were analysed using chi-squared test for trend. 
Page 28 of 47





























































Spearman rank analysis was used to test for univariate relationships between plasma 
ADMA and SDMA concentrations and other clinical variables including age, body 
mass index (BMI), mean arterial blood pressure (MABP), haemoglobin, GFR and 
plasma creatinine. Multiple linear regression analysis was used to assess the 
independent effect of clinical variables (age, gender, BMI, MABP, GFR, number of 
medications, haemoglobin, presence of vascular disease, hypertension and smoking 
status) on plasma ADMA and SDMA concentrations. Manual backward elimination 
was performed; clinical variables that were not significant (P>0.05) were eliminated 
from the analysis. Multicollinearity was not detected in any models used. 
Survival analysis (all-cause mortality) was studied using the Kaplan-Meier method. 
Significance between risk stratification groups (plasma ADMA and SDMA 
concentration above and below the median value) was determined using the 
Wilcoxon log-rank statistical test. Cox proportional hazard ratio was used to 
determine the association of variables with the risk of all cause death. Unadjusted 
hazard ratios (HRs) and the 95% confidence interval were calculated for plasma 
ADMA and SDMA concentration, age, gender, BMI, MABP, GFR, number of 
medications, haemoglobin concentration, diabetes mellitus, smoking status and 
hypertension. HRs and 95% confidence intervals were expressed per 1SD higher 
value of each variable for continuous variables. Cox regression analysis was 
performed with adjustment for the significant variables. Manual backward elimination 
was performed; clinical variables that were not significant (P>0.05) were excluded 
from the analysis. Multicollinearity was not detected in any models used.
Results
The East Kent cohort has been described previously.16 Briefly, subjects ranged in 
age from 74 to 97 years and were exclusively white. Approximately equal numbers of 
men and women were included. Characteristics overall and by GFR category are 
summarised in Table 1. Age and number of medications increased and haemoglobin 
concentration decreased with declining GFR. The prevalence of vascular disease, 
diabetes mellitus and hypertension increased with declining GFR. 
Plasma ADMA concentrations were increased (P<0.01) in people with GFR <60 
mL/min/1.73 m² compared to those with GFR >60 mL/min/1.73 m², but did not differ 
(P>0.05) between GFR category 30-59 mL/min/1.73 m² and <30 mL/min/1.73 m². 
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Conversely plasma SDMA increased consistently across declining GFR categories 
(P<0.0001)(Table 1). In univariate analyses both plasma ADMA and SDMA 
concentrations increased with declining GFR (Table 2, Figure 1). Plasma SDMA but 
not ADMA concentration was positively correlated (P<0.0001) with age (Table 2). 
Plasma SDMA concentration (median, interquartile range) was significantly higher 
(P<0.0001) in males (median 762, range 379 627 to 2240 1033 nmol/L) than in 
females (median 617, range 104 513 to 1870 823 nmol/L): plasma ADMA 
concentration did not differ between genders (P>0.05). 
GFR was the only variable which had an independent effect on plasma ADMA 
concentration. The fit (R²) of the model including GFR as a variable was 0.20. GFR, 
gender, BMI and haemoglobin had independent effects on plasma SDMA 
concentration. The overall fit (R²) of the model including these three variables was 
0.69 (P<0.0001)(Table 3).
All participants were followed up for a median (interquartile range) period of 33 (26-
43) months (IQR =26-43 months). During the follow up period, 65 people died. 
Seventy-two percent of the individuals that died had plasma ADMA concentrations 
greater than or equal to the median plasma ADMA concentration 4V7;- nmol/L). 
When the end point of the follow up period was considered as 48 months the survival 
chances for people with plasma ADMA concentrations V7;- nmol/L compared to 
<543 nmol/L were 68% and 89% respectively (P=0.0009) (Figure 2). The median 
plasma SDMA concentration was 680 nmol/L: 83% of the individuals that died had 
plasma SDMA concentrations V01. nmol/L. When the end point of the follow up 
period was considered as 48 months the survival chances for people with plasma 
SDMA concentrations V01. nmol/L compared to <680 nmol/L were 65% and 93% 
respectively (P<0.0001)(Figure 2).
Cox proportional hazard ratios were calculated to determine the significance of 
variables as predictors of all cause death. In unadjusted analyses ADMA, SDMA, 
age, GFR, number of medications, haemoglobin, presence of vascular disease and 
smoking status were significant predictors (Table 4). Manual backward elimination 
with stepwise elimination of insignificant variables was undertaken in two separate 
models including ADMA or SDMA. In the final ADMA model age, GFR, presence of 
vascular disease and smoking status in addition to plasma ADMA concentration 
remained significant independent predictors of all cause death. In the final SDMA 
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model age and smoking status in addition to plasma SDMA concentration remained 
significant (Table 4).  
Discussion
To our knowledge this is the first study to evaluate ADMA and SDMA as markers of 
both GFR and outcome in an exclusively elderly cohort across a range of kidney 
function in conjunction with a reference GFR measurement. In this study both ADMA 
and SDMA were inversely related to GFR. This relationship was stronger for SDMA 
than ADMA. Whilst ADMA concentration was influenced by GFR only, SDMA 
concentration was also affected by gender, BMI and haemoglobin concentration. 
ADMA predicted mortality risk, but this effect only just achieved significance with age, 
GFR, presence of vascular disease and smoking history all contributing strongly and 
independently to risk. Conversely, SDMA was a highly significant predictor of death 
in this cohort, with age and smoking history but not GFR contributing to risk in this 
model.
The strength of the relationship we observed between GFR and ADMA (rs=-0.42) is 
broadly similar to that observed in other cohorts (r-0.24,9 r-0.29,5 r=-0.2620), and not 
of sufficient strength to suggest that ADMA could be a useful marker on its own of 
GFR. Whilst SDMA is mainly eliminated through the kidneys,14 ADMA is mainly 
metabolised through enzymatic degradation in both the liver and kidney involving 
dimethylarginine dimethylaminohydrolase (DDAH). Consequently the relationship 
between ADMA and GFR may be confounded by hepatic function.21-23 In a 
retrospective analysis of participants in the Modification of Diet in Renal Disease 
Study, Young et al also found GFR to be the only variable tested to be significantly 
associated with ADMA concentration, but their model only explained 5% of the 
variability in ADMA concentration.24
There has been extensive study of the relationship between SDMA and GFR.25 
SDMA shows some of the properties of an ideal glomerular filtration marker, 
including being produced at a constant rate and being almost completely eliminated 
from the body by renal excretion.14 The strong relationship we have observed 
between SDMA and GFR (rs=-0.87) is consistent with that from other studies,20, 25, 26 
particularly those that also used a reference GFR technique where observed 
correlation coefficients ranged from 0.78 to 0.90.25 The SDMA-GFR relationship was 
also similar to that we observed between serum creatinine and GFR (rs=-0.87) and 
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for the proposed GFR marker cystatin C (rs=-0.90, data not shown) in this group. 
SDMA has also been shown to be an early and sensitive marker of abrupt change in 
kidney function following kidney donation.27 In addition to being related to GFR, 
plasma SDMA concentration is also strongly affected by gender, raising the 
possibility that GFR prediction from SDMA could be improved by models that also 
take gender into account.
Given the clear pathophysiological construct linking ADMA and vascular dysfunction, 
many studies have addressed the relationship between increased circulating ADMA 
concentration and mortality risk across a variety of populations,22, 28-30 including 
amongst older people.31 In the setting of kidney disease, an early study in dialysis 
patients showed that ADMA, but not SDMA, predicted mortality.32 In several cohorts 
of CKD patients, and amongst renal transplant recipients,33 high ADMA concentration 
was an independent predictor of all-cause mortality.5, 9 Conversely, in the study of 
Young et al amongst patients with moderate to severe CKD, ADMA did not reach 
significance as an independent predictor of all-cause mortality, although it was a 
significant predictor of cardiovascular mortality.24 
Fewer studies have explored the relationship between SDMA and mortality risk but 
increasing evidence suggests a role. In a German study of individuals receiving 
coronary angiography following an ischaemic event, SDMA demonstrated a J-shaped 
relationship with all-cause and cardiovascular mortality whereas the ADMA-mortality 
relationship was more linear.26 SDMA, but not ADMA, was independently associated 
with survival after stroke,34 non-ST elevation myocardial infarction20 and amongst 
individuals admitted to an intensive care unit.35 
Part of the association between SDMA and risk of mortality may reflect the strong 
relationship between GFR itself and risk. Indeed, the strong relationship between 
SDMA and GFR probably explains why only one of these factors remained significant 
in our adjusted model. A relationship between SDMA and mortality independent of 
GFR has also been reported in renal transplant recipients.36 Recent evidence 
suggests potential direct pathophysiological links between SDMA and cardiovascular 
disease through indirect inhibition of nitric oxide synthesis.15 The proposed 
mechanism is through competition with L-arginine for transport, hence limiting the 
availability of L-arginine to nitric oxide synthase.37 In turn, reactive oxygen species 
may further promote intracellular ADMA formation.38  Dose-dependent inhibition of 
nitric oxide synthesis by SDMA has been observed in cultured endothelial cells, 
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coupled with increased production of reactive oxygen species.15 In vitro SDMA, but 
not ADMA, was shown to cause release of proinflammatory cytokines (interleukin-6, 
IL-6; tumour necrosis factor-a, TNF-a) from monocytes: release of cytokines was 
linked to activation of nuclear factor-Kappa B.39 In vivo, plasma SDMA concentration 
was correlated to IL-6 and TNF-a concentrations amongst patients with CKD, with 
much weaker relationships observed for ADMA and cytokine concentrations.39 
SDMA, but not ADMA, concentrations have previously been observed to be 
independently increased in patients with coronary vascular disease and related to 
extent of such disease.15 There is therefore increasing evidence suggesting that 
SDMA could contribute to endothelial dysfunction and the chronic inflammatory state 
characteristic of CKD, with attendant increase in cardiovascular risk.
The strengths of this study include the simultaneous measurement of ADMA and 
SDMA across a well-characterised, large number of subjects covering a spectrum of 
kidney disease assessed using a reference GFR technique. The study has some 
limitations. Only single baseline measures of the dimethylarginines were available. 
Only all-cause mortality data was collected: pathophysiologically one would 
anticipate the role of dimethylarginines to be more closely linked to cardiovascular 
mortality. However, although cardiovascular disease is the major cause of mortality 
amongst people with CKD,12 other pathology including malignancy and infection40 
could be contributing to the relationship between mortality and SDMA due to 
increased SDMA production as a result of increased cell turnover. The study was 
exclusively white and findings may therefore not hold in other ethnic groups.41 In 
common with most studies in this field, plasma concentrations of dimethylarginines 
were measured. Any effects in vivo are likely to be related to intracellular 
dimethylarginine concentrations. Plasma concentrations of dimethylarginines may not 
reflect their intracellular concentration, potentially obscuring their true relationship 
with mortality.42
In conclusion we have shown that amongst elderly white individuals and across a 
range of kidney function, SDMA appears to be both a better marker of GFR and a 
stronger predictor of outcome than ADMA. The prognostic power of SDMA may be 
related to its more recently described roles in stimulating the pro-inflammatory state. 
Future studies should further evaluate the role of SDMA as a marker of outcome and 
assess its potential value as a marker of GFR.
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Figure 1A. Scatter plot of 1/plasma ADMA in association with measured 
glomerular filtration rate (mG  p <0.0001
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Figure 1 Scatter plot of 1/plasma SDMA in association with measured 
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Figure 2a. Kaplan-Meier survival curve by median ADMA concentration (543 nmol/L); P .
 ADMA 8 543 nmol/L
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Figure 2b. Kaplan-Meier survival curve by median SDMA concentratio P<0.0001.
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cteristics by GFR category. Values for continuous variables are expressed as median (interquartile interquartile 
range) unless stated otherwise. P<0.05 was considered significant. 
 cohort 8;+ mL/min/1.73  39 min3  <3 ﬀn3  P for trend
n  394 163 171 60 -
Male:female, n (% male) 189:205 67:96 (41) 90:81 (53) 33:28 (55) 0.0617
Age, y 80 (774 - 8397) 79 (764 - 819)a, b 80 (774 - 8497) 81 (775 - 8697) <0.0001




26.2 (16.424.1 - 47.629.7) 27.3 (17.323.9 - 
39.330.0)
0.0998
MABP, mm Hg* 96.05.7 (89.360.0 - 
144.3103.6)
94.3 (6087.3 - 
144.3104.4)
96.6 (74.391.4 - 
133.3104.8)
96.3 (72.087.1 - 
128.6100.9)
0.4100
Number of medications, n 5 (30 - 18) 4 (0 1 - 176)a, b 6 (0 4 - 18) 7 (50 - 105) <0.0001
Vascular disease, n (%) 172 (44) 49 (31)a 90 (53) 33 (54) <0.0001
Diabetes, n (%) 77 (20) 21 (13)b 36 (21) 20 (33) 0.0032
Hypertension, n (%) 251 (55) 71 (44)a, b 104 (61) 40 (66) 0.0014
Smoker, n (%) 86 (22) 26 (16)a 51 (30)c 9 (15) 0.0034
Haemoglobin, g/L 130 (12077-139168) 136 (93129-14268)a, b 126 (11777-164136)c 118 (90118-54129) <0.0001
Serum creatinine, µmol/L 94.5 (34.873 - 
382.0144)
71.4 (34.861 - 306.884) 1110.5 (53.788 - 
282.1145)
191.0 (91.1157 - 
382247.0)
-
GFR, mL/min/1.73 m² 53 (357-68101) 69 (6064-10178) 45 (360-529) 25 (227-279) -
ADMA, nmol/L 543 (49893- 874608) 521 (364472-723559) a, 
b
565 (51393-624841) 595 (443526-874673) <0.0001
SDMA, nmol/L 680 (104542-2240927) 530 (379480-1170610) 
a, b 
775 (104663-1650934)c 1220 (7081067-
22401390)
<0.0001
*MABP data was obtained for 374 patients in total and 154, 163 and 57 patients in the >60, 30-59 and <30 mL/min/1.73 m2 groups respectively.
Abbreviations: ADMA, asymmetric dimethylarginine; BMI, Body mass index; GFR, measured glomerular filtration rate (using iohexol); MABP, mean arterial 
blood pressure; SDMA, symmetric dimethylarginine;.
Dunn's multiple comparison test for pairwise comparisons of the effect of GFR category on plasma ADMA, SDMA and serum cystatin C concentration are 
denoted as shown below.
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a P<0.05 for V0. mL/min/1.73 m² vs. 30-59 mL/min/1.73 m²
b P<0.05 for V0. mL/min/1.73 m² vs. <30 mL/min/1.73 m²
c P<0.05 for 30-59 mL/min/1.73 m² vs. <30 mL/min/1.73 m²







Serum creatinine 0#+'& 0#)*&
Note. Values expressed as correlation coefficients obtained using Spearmans rank statistic. Statistical significance is shown as & (P<0.0001 in each case); 
the remaining correlations were not statistically significant.
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Abbreviations: ADMA, asymmetric dimethylarginine; BMI, body mass index; GFR, measured glomerular filtration rate (using iohexol); MABP, mean arterial 
blood pressure; SDMA, symmetric dimethylarginine; 
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ct of clinical variables on plasma ADMA and SDMA concentrations. Values shown are the beta coefficients (95% confidence 
intervals) for the variables that remained significant in the multiple regression model.
ADMA SDMA
Constant 664.1 (641.5 to 686.6), P<0.0001 1828.1 (1654.1 to 2002.0), P<0.0001
Glomerular filtration rate -2.032 (-2.436 to -1.628), P<0.0001 -11.779 (-12.791 to -10.768), P<0.0001
Haemoglobin - -2.723   (-3.968 to -1.478), P<0.0001
Gender - 98.416 (63.281 to 133.55), P<0.0001
Body mass index - -4.907 (-8.699 to -1.116), P=0.0116
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Unad sted rd ratios for death. For continuous variables, the hazard ratios are expressed as the increased risk 
associated with a one standard deviation increase (ADMA, age, BMI, MABP, medication no.) or decrease (GFR, haemoglobin). For categorical 
variables, the hazard ratios are expressed as risk if conditions present (vascular disease, hypertension, smoker and diabetes mellitus) or if 










ADMA, nmol/ L 1.67 (1.32 - 2.10) <0.0001 1.30 (1.01-1.68) 0.0412 - -
SDMA, nmol/L 2.01 (1.66 - 2.44) <0.0001 - - 2.43 (1.80  3.28)  <0.0001
Age, years 1.65 (1.36  2.00) <0.0001 1.43 (1.17  1.75) 0.0005 1.47 (1.20 - 1.81) 0.0003
Gender (f/m) 1.42 (0.87 - 2.32) 0.1651a - -
BMI, weight(kg)/height(m)² 0.95 (0.74 - 1.21) 0.6593 - -
MABP, mmHg 0.99 (0.77 - 1.27) 0.9265 - -
GFR, mL/min/1.73 m² 0.44 (0.33 - 0.59) <0.0001 0.54 (0.39  0.76) 0.0003
Number of medications, n 1.39 (1.11 - 1.75) 0.0045 - -
Haemoglobin, g/L 0.63 (0.46 - 0.85) 0.0032 - -
Vascular Disease (y/n) 2.61 (1.56  - 4.37) a 1.91 (1.14  3.21)a 0.0145
Diabetes (y/n) 1.42 (0.82 - 2.48) 0.2143a - -
Smoker (y/n) 2.14 (1.30 - 3.53) a 1.87 (1.13  3.10)a 0.0155 1.99 (1.20 - 3.29)a 0.0074
Hypertension (y/n) 1.38 (0.84 - 2.29) 0.2061a - -
Abbreviations: ADMA, asymmetric dimethylarginine; BMI, Body mass index;  CI, confidence interval; GFR, glomerular filtration rate (using iohexol); MABP, 
mean arterial blood pressure; SDMA, symmetric dimethylarginine
a adjusted hazard ratio (95% CI) for presence compared to absence or female versus male
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